These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38069716)

  • 1. Current HDAC Inhibitors in Clinical Trials.
    Di Bello E; Noce B; Fioravanti R; Mai A
    Chimia (Aarau); 2022 May; 76(5):448-453. PubMed ID: 38069716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
    Hamminger P; Rica R; Ellmeier W
    Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Histone Deacetylases in Diseases: Where Are We?
    Benedetti R; Conte M; Altucci L
    Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
    Mody D; Bouckaert J; Savvides SN; Gupta V
    Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
    Kee HJ; Kim I; Jeong MH
    Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histone deacetylases for cancer therapy: Trends and challenges.
    Liang T; Wang F; Elhassan RM; Cheng Y; Tang X; Chen W; Fang H; Hou X
    Acta Pharm Sin B; 2023 Jun; 13(6):2425-2463. PubMed ID: 37425042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.
    Ruzic D; Djoković N; Srdić-Rajić T; Echeverria C; Nikolic K; Santibanez JF
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
    Krishna S; Kumar V; Siddiqi MI
    Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
    Sharma NL; Groselj B; Hamdy FC; Kiltie AE
    BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
    Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
    Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
    Hsu KC; Liu CY; Lin TE; Hsieh JH; Sung TY; Tseng HJ; Yang JM; Huang WJ
    Sci Rep; 2017 Jun; 7(1):3228. PubMed ID: 28607401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in class IIa histone deacetylases research.
    Asfaha Y; Schrenk C; Alves Avelar LA; Hamacher A; Pflieger M; Kassack MU; Kurz T
    Bioorg Med Chem; 2019 Nov; 27(22):115087. PubMed ID: 31561937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
    Turtoi A; Peixoto P; Castronovo V; Bellahcène A
    Crit Rev Oncog; 2015; 20(1-2):119-37. PubMed ID: 25746107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylases and their Inhibitors in Cancer Epigenetics.
    Hassell KN
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31683808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors: Promising agents for leukemia treatment.
    Deng Y; Cheng Q; He J
    Biochem Biophys Res Commun; 2023 Nov; 680():61-72. PubMed ID: 37722346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase (HDACs) inhibitors: Clinical applications.
    Shanmukha KD; Paluvai H; Lomada SK; Gokara M; Kalangi SK
    Prog Mol Biol Transl Sci; 2023; 198():119-152. PubMed ID: 37225317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.